Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial

What we doOur approachPipelineTechnologyPublications
About usExecutive ManagementBoard of DirectorsScientific Advisory Board
News & eventsPress releasesEventsInterviews
Investors
Careers

Back
Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial 
 8:00:00 AM

Keep reading
Immunicum AB (publ) Announces Publication of Scientific Review of Ilixadencel Approach in Pharmaceutical ResearchRead